NLRP3 and inflammatory bowel disease: In summary, Atractylenolide I ameliorates IBD by inhibiting DRP1-mediated activation of mitochondrial fission-induced NLRP3 inflammatory vesicles and suggests a detrimental effect associated with excessive activation of DRP1 in IBD.